HUP0203521A2 - Kristályos 4-karboxi-amino-2-etil-1,2,3,4-tetrahidro-kinolin CEPT inhibitor, eljárás az előállítására, ezt tartalmazó gyógyszerkészítmény és alkalmazása - Google Patents
Kristályos 4-karboxi-amino-2-etil-1,2,3,4-tetrahidro-kinolin CEPT inhibitor, eljárás az előállítására, ezt tartalmazó gyógyszerkészítmény és alkalmazásaInfo
- Publication number
- HUP0203521A2 HUP0203521A2 HU0203521A HUP0203521A HUP0203521A2 HU P0203521 A2 HUP0203521 A2 HU P0203521A2 HU 0203521 A HU0203521 A HU 0203521A HU P0203521 A HUP0203521 A HU P0203521A HU P0203521 A2 HUP0203521 A2 HU P0203521A2
- Authority
- HU
- Hungary
- Prior art keywords
- carboxyamino
- tetrahydroquinoline
- ethyl
- crystal
- preparation
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- OXMLOGDTDJEBJR-UHFFFAOYSA-N (2-ethyl-1,2,3,4-tetrahydroquinolin-4-yl)carbamic acid Chemical compound C1=CC=C2NC(CC)CC(NC(O)=O)C2=C1 OXMLOGDTDJEBJR-UHFFFAOYSA-N 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16805199P | 1999-11-30 | 1999-11-30 | |
| PCT/IB2000/001650 WO2001040190A1 (en) | 1999-11-30 | 2000-11-14 | 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0203521A2 true HUP0203521A2 (hu) | 2003-02-28 |
Family
ID=22609901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0203521A HUP0203521A2 (hu) | 1999-11-30 | 2000-11-14 | Kristályos 4-karboxi-amino-2-etil-1,2,3,4-tetrahidro-kinolin CEPT inhibitor, eljárás az előállítására, ezt tartalmazó gyógyszerkészítmény és alkalmazása |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP1246804A1 (es) |
| JP (1) | JP2003515592A (es) |
| KR (1) | KR20020058057A (es) |
| CN (1) | CN1402711A (es) |
| AP (1) | AP2002002531A0 (es) |
| AU (1) | AU1048801A (es) |
| BG (1) | BG106854A (es) |
| BR (1) | BR0015836A (es) |
| CA (1) | CA2392979A1 (es) |
| CO (1) | CO5271716A1 (es) |
| EA (1) | EA200200510A1 (es) |
| EC (1) | ECSP003792A (es) |
| EE (1) | EE200200277A (es) |
| GT (1) | GT200000199A (es) |
| HU (1) | HUP0203521A2 (es) |
| IL (1) | IL149097A0 (es) |
| IS (1) | IS6338A (es) |
| MA (1) | MA26845A1 (es) |
| MX (1) | MXPA02005354A (es) |
| NO (1) | NO20022558L (es) |
| OA (1) | OA12099A (es) |
| PA (1) | PA8506301A1 (es) |
| PE (1) | PE20010904A1 (es) |
| PL (1) | PL355892A1 (es) |
| TN (1) | TNSN00231A1 (es) |
| TR (1) | TR200201446T2 (es) |
| UY (1) | UY26454A1 (es) |
| WO (1) | WO2001040190A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| KR20040015746A (ko) | 2001-06-21 | 2004-02-19 | 화이자 프로덕츠 인크. | 콜레스테릴 에스테르 전달 단백질 억제제의 자가 에멀젼화제제 |
| GT200200170A (es) * | 2001-09-28 | 2003-05-23 | Preparacion de inhibidor de cetp anhidro | |
| BR0307333A (pt) * | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Métodos para a preparação de dispersões homogéneas de fármacos sólidos amorfos atomizados utilizando um sistema de secagem por pulverização |
| BR0307344A (pt) | 2002-02-01 | 2004-12-14 | Pfizer Prod Inc | Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica |
| EP1920766B1 (en) * | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
| EP1533292B1 (en) | 2002-08-30 | 2007-02-14 | Japan Tobacco Inc. | Dibenzylamine compound and medicinal use thereof |
| US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| KR20050055747A (ko) | 2002-10-04 | 2005-06-13 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 염증 질환 치료용의 ｐｇｄ2 수용체 길항제 |
| AU2003283769A1 (en) | 2002-12-20 | 2004-07-14 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| KR100729883B1 (ko) * | 2003-03-28 | 2007-06-18 | 화이자 프로덕츠 인코포레이티드 | 죽상경화증 및 비만증을 치료하기 위한 ｃｅｔｐ억제제로서의 1,2,4-치환된 1,2,3,4-테트라하이드로- 및1,2-디하이드로-퀴놀린 및1,2,3,4-테트라하이드로-퀴녹살린 유도체 |
| EP1653927B1 (en) | 2003-08-04 | 2012-01-11 | Bend Research, Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
| PL1670768T3 (pl) | 2003-10-08 | 2010-01-29 | Lilly Co Eli | Związki i sposoby leczenia dyslipidemii |
| WO2005100298A1 (en) * | 2004-04-13 | 2005-10-27 | Merck & Co., Inc. | Cetp inhibitors |
| KR20070041452A (ko) * | 2004-06-24 | 2007-04-18 | 일라이 릴리 앤드 캄파니 | 이상지혈증 치료를 위한 화합물 및 방법 |
| US20070149567A1 (en) * | 2004-09-23 | 2007-06-28 | Pfizer Inc | Quinoline compounds |
| WO2006033001A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
| MX2007010215A (es) | 2005-02-24 | 2007-11-07 | Millennium Pharm Inc | Antagonistas del receptor pgd2 para el tratamiento de enfermedades inflamatorias. |
| WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| AR065670A1 (es) | 2007-03-09 | 2009-06-24 | Indigene Pharmaceuticals Inc | Combinacion de metformina r-(+) lipoato y agentes antihiperlipidemicos para el tratamiento de hiperglucemia diabetica y complicaciones diabeticas |
| EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
| AR077208A1 (es) | 2009-06-30 | 2011-08-10 | Lilly Co Eli | Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam |
| RU2703192C2 (ru) | 2014-07-30 | 2019-10-15 | Ф. Хоффманн-Ля Рош Аг | Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
| AU5731098A (en) * | 1997-02-03 | 1998-08-25 | American Home Products Corporation | 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
-
2000
- 2000-11-09 CO CO00085285A patent/CO5271716A1/es unknown
- 2000-11-13 PA PA20008506301A patent/PA8506301A1/es unknown
- 2000-11-14 AU AU10488/01A patent/AU1048801A/en not_active Abandoned
- 2000-11-14 TR TR2002/01446T patent/TR200201446T2/xx unknown
- 2000-11-14 JP JP2001541875A patent/JP2003515592A/ja active Pending
- 2000-11-14 EP EP00971662A patent/EP1246804A1/en not_active Withdrawn
- 2000-11-14 OA OA1200200158A patent/OA12099A/en unknown
- 2000-11-14 IL IL14909700A patent/IL149097A0/xx unknown
- 2000-11-14 WO PCT/IB2000/001650 patent/WO2001040190A1/en not_active Application Discontinuation
- 2000-11-14 HU HU0203521A patent/HUP0203521A2/hu unknown
- 2000-11-14 CA CA002392979A patent/CA2392979A1/en not_active Abandoned
- 2000-11-14 EE EEP200200277A patent/EE200200277A/xx unknown
- 2000-11-14 BR BR0015836-4A patent/BR0015836A/pt not_active IP Right Cessation
- 2000-11-14 MX MXPA02005354A patent/MXPA02005354A/es unknown
- 2000-11-14 EA EA200200510A patent/EA200200510A1/ru unknown
- 2000-11-14 KR KR1020027006914A patent/KR20020058057A/ko not_active Application Discontinuation
- 2000-11-14 AP APAP/P/2002/002531A patent/AP2002002531A0/en unknown
- 2000-11-14 PL PL00355892A patent/PL355892A1/xx not_active Application Discontinuation
- 2000-11-14 CN CN00816463A patent/CN1402711A/zh active Pending
- 2000-11-28 UY UY26454A patent/UY26454A1/es not_active Application Discontinuation
- 2000-11-28 PE PE2000001267A patent/PE20010904A1/es not_active Application Discontinuation
- 2000-11-29 EC EC2000003792A patent/ECSP003792A/es unknown
- 2000-11-29 TN TNTNSN00231A patent/TNSN00231A1/fr unknown
- 2000-11-29 GT GT200000199A patent/GT200000199A/es unknown
-
2002
- 2002-04-12 IS IS6338A patent/IS6338A/is unknown
- 2002-05-27 MA MA26653A patent/MA26845A1/fr unknown
- 2002-05-29 NO NO20022558A patent/NO20022558L/no not_active Application Discontinuation
- 2002-06-20 BG BG106854A patent/BG106854A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA26845A1 (fr) | 2004-12-20 |
| IL149097A0 (en) | 2002-11-10 |
| PL355892A1 (en) | 2004-05-31 |
| BG106854A (bg) | 2002-12-29 |
| EP1246804A1 (en) | 2002-10-09 |
| TNSN00231A1 (fr) | 2002-05-30 |
| PE20010904A1 (es) | 2001-09-10 |
| CA2392979A1 (en) | 2001-06-07 |
| KR20020058057A (ko) | 2002-07-12 |
| AP2002002531A0 (en) | 2002-06-30 |
| BR0015836A (pt) | 2002-08-06 |
| EA200200510A1 (ru) | 2002-10-31 |
| MXPA02005354A (es) | 2002-12-11 |
| NO20022558D0 (no) | 2002-05-29 |
| EE200200277A (et) | 2003-10-15 |
| CO5271716A1 (es) | 2003-04-30 |
| GT200000199A (es) | 2002-05-23 |
| OA12099A (en) | 2006-05-04 |
| TR200201446T2 (tr) | 2002-11-21 |
| AU1048801A (en) | 2001-06-12 |
| JP2003515592A (ja) | 2003-05-07 |
| UY26454A1 (es) | 2001-07-31 |
| WO2001040190A1 (en) | 2001-06-07 |
| NO20022558L (no) | 2002-05-29 |
| PA8506301A1 (es) | 2002-08-26 |
| CN1402711A (zh) | 2003-03-12 |
| ECSP003792A (es) | 2002-04-23 |
| IS6338A (is) | 2002-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0203521A2 (hu) | Kristályos 4-karboxi-amino-2-etil-1,2,3,4-tetrahidro-kinolin CEPT inhibitor, eljárás az előállítására, ezt tartalmazó gyógyszerkészítmény és alkalmazása | |
| HUP0303084A2 (hu) | Gyulladásgátló hatású 17béta-karbotioát-17alfa-arilkarboniloxiloxi androsztán-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0002987A2 (hu) | Cefdinir diciklohexil-amin sója és eljárás a só előállítására valamint a vegyület sójából történő felszabadítására | |
| HUP0302519A2 (hu) | Az atorvasztatin kristályos formái, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0102813A2 (hu) | Perindopril-terc-butil-amin-só új béta-kristályos formája, eljárás ennek előállítására és ezt tartalmazó gyógyászati készítmények | |
| HUP0300434A2 (hu) | Oxazolszármazékok és alkalmazásuk tirozin-kináz-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| IL150482A0 (en) | Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | |
| ATE240316T1 (de) | Heteroaromatische amide als inhibitoren von faktor xa | |
| PT915898E (pt) | Forma i cristalina de claritromicina | |
| MXPA02011425A (es) | Derivados sustituidos de pirrolopiridinona utiles como inhibidores de fosfodiesterasa. | |
| HUP0302475A2 (hu) | Eljárás allergia kezelésére szubsztituált pirazolok alkalmazásával | |
| ATE301995T1 (de) | Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen | |
| MY106202A (en) | Saccharin derivatives useful as proteolytic enzyme inhibitors and preparation thereof. | |
| HUP0301076A2 (hu) | Linezolid II kristályforma és előállítása | |
| HUP0303034A2 (hu) | Új 7-azaindol-származékok, foszfodiészteráz-4 inhibitorjakénti alkalmazásuk és eljárás az előállításukra | |
| IL149586A0 (en) | Pyrimidine derivatives as selective inhibitors of cox-2 | |
| HUP0200580A2 (hu) | Celecoxib polimorf kristályos formái, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0302479A2 (hu) | NF-kappa B gátló gyógyszerkészítmény, amely hatóanyagként helyettesített benzoesavszármazékot tartalmaz | |
| AU2364000A (en) | Heterocyclic amides as inhibitors of factor xa | |
| HUP0105308A2 (hu) | Eletriptán-hidrobromid-monohidrát, eljárás az előállítására és a vegyületet tartalmazó gyógyszerkészítmények | |
| HUP0402602A2 (hu) | Eljárás echinokandin-származékok előállítására, ezek alkalmazása, ezeket tartalmazó gyógyszerkészítmények és intermedierek | |
| AU2003271811A1 (en) | Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same | |
| NO20010559D0 (no) | Fremgangsmåte for syntese av (1H)-benzo[c]kinolizin-3-ones derivater | |
| HUP0401234A2 (hu) | Pravastatin stabil gyógyászati kompozíciója és eljárás az előállítására | |
| HUP0303760A2 (hu) | AZ NF-kB faktort gátló szubsztituált benzoesavszármazékok és ezeket tartalmazó gyógyszerkészítmények |